Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Treatment benefits of simultaneous initiation and combination therapy with the nonsteroidal mineralocorticoid receptor antagonist finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin, in reducing urinary albumin-to-creatinine ratio (UACR) in the CONFIDENCE trial (NCT05254002) have been reported. Progression of chronic kidney disease (CKD) may differ by patient demographic characteristics, including age and sex. We therefore evaluated the efficacy and safety profile of combination therapy with finerenone and empagliflozin by age and sex subgroups in the CONFIDENCE trial.
The CONFIDENCE trial enrolled adults with CKD and type 2 diabetes with a UACR of 100 to <5000 mg/g, an estimated glomerular filtration rate of 30 to 90 mL/min/1.73 m2, and on a renin-angiotensin system inhibitor. Participants were randomized 1:1:1 to once-daily finerenone (10 or 20 mg) plus empagliflozin (10 mg), finerenone (10 or 20 mg) plus placebo, or empagliflozin (10 mg) plus placebo. In an exploratory analysis, treatment effects on the primary endpoint of relative change in UACR from baseline at Day 180 were assessed by age and sex subgroups. Safety outcomes were also assessed.
In CONFIDENCE, mean age (years [standard deviation]) of participants in the full analysis set (N=800) was 66.5 (10.3). There were 198 (24.8%) female participants. Combination therapy reduced UACR to a generally greater extent than finerenone or empagliflozin alone in the age and sex subgroups at Day 180. Older age was associated with lower estimated glomerular filtration rate and greater prevalence of atherosclerotic cardiovascular disease at baseline. Increasing age at baseline was a significant predictor of UACR reduction, with a −10.2% (95% CI [confidence interval] −15.5% to −4.6%) incremental change per 10-year age increase at Day 180. At Day 180, female participants exhibited −18.6% (95% CI −29.2% to −6.3%) greater UACR reduction compared to male participants. These effects were independent of treatment group. Safety outcomes were consistent across all demographics.
In this analysis of combination therapy with finerenone and empagliflozin in CONFIDNCE, we found that efficacy scales linearly with age (approximately 10% greater UACR reduction per decade) and sex (approximately 20% greater UACR reduction among females). The intervention was well-tolerated across all age and sex subgroups. Both advancing age and female sex are associated with an enhanced UACR-lowering response without compromising the safety profile.
